Patent classifications
A61K2236/50
Method of microalgal biomass processing for high-value chemicals production, the resulting composition of butyrogenic algal slowly fermenting dietary fiber, and a way to improve colon health using a slowly fermenting butyrogenic algal dietary fiber
A method to process microalgae biomass and produce high-value chemicals from microalgae biomass is disclosed. The method uses the same biomass cells to extract more than one component such as are lipids, water-soluble chemicals, carotenoids, polysaccharides and algae meal. The method is a sequence of physical and chemical treatments. Water soluble polysaccharides produced by the method exhibit properties of low viscosity at low shear thinning. A method for extracting dietary fiber from microalgal biomass is disclosed. Compositions of water-soluble polysaccharides that are fermented slowly by colon microbiota with less gas production than commercial dietary fiber FOS are disclosed. The present inventions described herein provide a method of improving colon health by increasing butyrate during a microalgal dietary fiber fermenting process by colonic microbiota.
CBX EXTRACTION-ISOLATION PROCESS
The present invention relates generally to improved methods for the extraction and isolation of cannabinoids from hemp. More particularly, the present invention relates to a series of extraction and isolation processes employed to selectively enhance recovery of non-psychoactive cannabinoids and the like, from cannabis materials and extracts, while removing undesirable naturally occurring components that may be present including colorants, carbohydrates, sugars and waxes, and the like, as well as contaminants that may be present in source materials including bactericides, fungicides, insecticides, plant growth regulators, environmental pollutants, and processing aids, and the like. The present invention further relates to an isolate obtained using a series of extraction and isolation processes that has extremely high cannabinoid content present in a stable, flowable liquid form that is essentially free of detectable levels of psychoactive cannabinol components.
CHARDONNAY GRAPE SEED EXTRACT
A novel grape seed extract is enriched in procyanidins, has total polyphenols of less than 70%, and has a low degree of polymerization (dp). Other fractions of the extract have minimal polyphenols, fiber, and protein, but contain more than 90% sugars. In some specific examples, the individual extracts are obtained by sequential ultrafiltration of a water extract of the grape seeds. A first ultrafiltration provides a first permeate (Fraction A) enriched in sugars which is useful as a flavorant, and a first retentate. The first retentate is reconstituted and subjected to a second ultrafiltration at a higher molecular weight cutoff to produce a second permeate (Fraction B) that is enriched in low molecular weight polyphenols, and a second retentate (Fraction C) that is enriched in seed fiber. The Fractions are individually suitable for different nutraceutical products, or can be combined with each other in any combination and/or with other nutraceutical agents to enhance vascular and cognitive health.
Chardonnay grape seed extract
A novel grape seed extract is enriched in procyanidins, has total polyphenols of less than 70%, and has a low degree of polymerization (dp). Other fractions of the extract have minimal polyphenols, fiber, and protein, but contain more than 90% sugars. In some specific examples, the individual extracts are obtained by sequential ultrafiltration of a water extract of the grape seeds. A first ultrafiltration provides a first permeate (Fraction A) enriched in sugars which is useful as a flavorant, and a first retentate. The first retentate is reconstituted and subjected to a second ultrafiltration at a higher molecular weight cutoff to produce a second permeate (Fraction B) that is enriched in low molecular weight polyphenols, and a second retentate (Fraction C) that is enriched in seed fiber. The Fractions are individually suitable for different nutraceutical products, or can be combined with each other in any combination and/or with other nutraceutical agents to enhance vascular and cognitive health.
COMPOSITIONS, KITS AND METHODS FOR TREATING TYPE II DIABETES MELLITUS
Disclosed herein are methods for treating type II diabetes mellitus. In particular, the present invention relates to methods of using an extract of Hedychium coronarium Koenig and a blood glucose reduction agent, to synergistically reduce the blood glucose level of the subject having type II diabetes mellitus.
ANTIBACTERIAL INDIGO NATURALIS OR INDIGO-PRODUCING PLANT EXTRACT AND USE THEREOF
A pharmaceutical or cosmetic composition is provided. The composition includes an Indigo Naturalis or Indigo-producing plant extract, for inhibiting Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus. A method of inhibiting Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus, is also provided. The method includes contacting a cell with an effective amount of an Indigo Naturalis or Indigo-producing plant extract.
HYDROLYSATE OF WATER EXTRACT OF GRACILARIOPSIS CHIANGII, AND PREPARATION PROCESS AND USE THEREOF
Disclosed herein are a hydrolysate of water extract of Gracilariopsis chiangii and a preparation process thereof. Also disclosed herein is a composition including the aforesaid hydrolysate of water extract of Gracilariopsis chiangii. The composition can be used in enhancing the moisture-retaining capacity of the skin, improving wound healing and reducing oxidative stress.
PROCESS TO OBTAIN A NUTRACEUTICAL FORMULATION OF AMARANTH AND ITS USE IN TREATING HUMAN BEHAVIOR DISORDERS
The present invention relates to a novel process to manufacture a nutraceutical formulation of amaranth, made from amaranth whole seeds. The nutraceutical formulation of amaranth obtained by the present invention has unique characteristics for addressing problems of great relevance in the priority field of public health, which significantly affects people in general, that is to say, the use in treating human behavioral disorders such as depression, stress, anxiety, and extreme cases like schizophrenia and bipolar disorder
Use of Extract from Morus alba L. in the Preparation of a Medicament for Preventing and/or Treating a Hepatobiliary Disease
The present invention discloses applications of extracts from Morus alba L. Disclosed by the present invention is a use of extracts from Morus alba L. in the preparation of a product for alleviating, preventing and/or treating a hepatobiliary disease. The present invention demonstrated experimentally that extracts from Morus alba L. have effects of reducing hepatic lipid content and alleviating hepatic fibrosis in NAFLD mice gavaged with extracts from Morus alba L., thereby alleviating high-fat diet-induced fatty liver without toxic and side effects on liver and kidney. The drug of the present invention exerts multi-target pharmacological effects through multi-components, and specifically can regulate the hepatic lipid content by regulating the synthesis and oxidation of fatty acids, and can also affect hepatic fibrosis, which is more conducive to the treatment of a non-alcoholic fatty liver disease.
COMPOSITIONS AND METHODS FOR TREATING, PREVENTING, AND IMPROVING RESPIRATORY SYMPTOMS
The present invention provides a method for pre-treating raw parsnips into aged parsnips and extracting the aged parsnips to produce parsnip extracts having higher biological activity than raw parsnips. Also, it provides a composition containing the parsnip extracts, and a method of using the composition to promote respiratory health and/or to prevent, improve, or treat respiratory symptoms or diseases.